Effect of combined administration of lansoprazole and sofalcone on microvascular and connective tissue regeneration after ethanol-induced gastric mucosal damage.
We undertook the present study to clarify the alteration of localization of basic fibroblast growth factor (bFGF), endothelial cells, and myofibroblasts in the healing of ethanol-induced gastric mucosal damage by the combined administration of lansoprazole and sofalcone. Wistar strain male rats were used. Ethanol 50% was given through orogastric intubation. Thirty minutes later, an aqueous solution of lansoprazole, sofalcone, a combination of lansoprazole and sofalcone, or physiologic saline was given orally. The stomach was removed and the localization of bFGF, myofibroblast, and endothelial cells was examined using monoclonal antibodies. Some rats were pretreated with indomethacin to rule out the effect of endogenous prostaglandin. The combined administration of lansoprazole and sofalcone brought about increased concentrations and immunoreactive areas of bFGF and a greater number of endothelial cells, compared with the ethanol-alone treatment. The number of myofibroblasts increased more significantly in the group treated with a combination of agents than in that treated with ethanol alone, ethanol plus sofalcone, or ethanol plus lansoprazole. Indomethacin pretreatment partly abolished the effects of single and combined administration of these agents. In conclusion, the mixed administration of lansoprazole and sofalcone accelerated the microvascular and connective tissue regeneration during the healing of ethanol-induced gastric mucosal damage.
Nakamura
M
M
Department of Internal Medicine, Tokyo Denryoku Hospital, Japan.
Akiba
Y
Y
Kishikawa
H
H
Oda
M
M
Ishii
H
H
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000818:Animals; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D018955:CD36 Antigens / Q000032:analysis; D002599:Chalcone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D047188:Chalcones; D003238:Connective Tissue / Q000502:physiology*; D004359:Drug Therapy, Combination; D004730:Endothelium, Vascular / Q000166:cytology / Q000502:physiology*; D000431:Ethanol; D016222:Fibroblast Growth Factor 2 / Q000032:analysis; D005347:Fibroblasts / Q000166:cytology; D005753:Gastric Mucosa / Q000737:chemistry / Q000473:pathology / Q000502:physiology; D007150:Immunohistochemistry; D007509:Irritants; D064747:Lansoprazole; D008297:Male; D008833:Microcirculation; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D012038:Regeneration; D013276:Stomach Ulcer / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D018955:CD36 Antigens; D047188:Chalcones; D007509:Irritants; D064747:Lansoprazole; D016222:Fibroblast Growth Factor 2; C035032:sofalcone; D000431:Ethanol; D002599:Chalcone; D009853:Omeprazole